Bioventus Acquires CartiHeal for $500M

Johnson & Johnson Options to Acquire Sail Biomedicines for $2.58 Billion

August 2, 2026

Biotechnology

Johnson & Johnson entered into strategic agreements with Sail Biomedicines to collaborate on in vivo CAR-T therapies and secured an exclusive option to acquire Sail for $2.58 billion. The deal includes initial payments totaling $785 million (including a $465 million equity investment) and up to $140 million in additional development milestone payments, with the $2.58 billion payable if the option is exercised.

Agilent Technologies Acquires Biocare Medical

March 9, 2026

Medical Devices

Agilent Technologies entered into a definitive agreement to acquire Biocare Medical, a global provider of clinical and research pathology solutions, for $950 million in an all-cash transaction. The acquisition expands Agilent’s pathology portfolio—particularly in immunohistochemistry (IHC)—and is expected to be accretive to Agilent’s top-line growth rate, margin profile, and non-instrument revenue mix in Year 1.

Accelmed Partners Acquires Bioventus' Bioness Advanced Rehabilitation Business

October 1, 2024

Medical Devices

Bioventus has signed a definitive agreement to sell the Advanced Rehabilitation business of its subsidiary Bioness to private equity firm Accelmed Partners for total cash consideration of $45 million (including up to $20 million in earn-outs). The divestiture reduces Bioventus' annual revenue by about $50 million and allows Bioventus to focus on its core business while Accelmed plans to invest in and expand the Bioness rehabilitation product line.

Smith+Nephew Acquires CartiHeal for up to $330 Million

November 24, 2023

Medical Devices

Smith+Nephew (S&N) has agreed to acquire Israeli medtech CartiHeal for up to $330 million, adding CartiHeal's Agili‑C implant to its Sports Medicine/knee repair portfolio. CartiHeal, founded in 2009 and headquartered in Kfar Saba, Israel, employs about 25 people and has FDA breakthrough-designated technology for osteochondral repair.

Bioventus Inc. Acquires Misonix, Inc.

July 29, 2021

Medical Devices

Bioventus Inc. entered into a definitive agreement to acquire Misonix, Inc. in a cash-and-stock transaction that values Misonix at approximately $518 million on a fully diluted basis. The deal expands Bioventus' regenerative medicine and surgical solutions portfolio by adding Misonix's minimally invasive ultrasonic technologies and regenerative wound products and is expected to close in the fourth quarter of 2021 subject to customary approvals.

Bioventus Acquires Bioness, Inc.

March 30, 2021

Medical Devices

Bioventus Inc. acquired Bioness, Inc. for $45 million in up-front consideration plus up to $65 million of contingent consideration, making Bioness a wholly‑owned subsidiary. The acquisition expands Bioventus' rehabilitation and neuromodulation product portfolio and R&D pipeline, and is expected to be accretive to revenue by leveraging Bioventus' global commercial infrastructure.